Home| Non-Clinical Lecturer in Bacteriology |
Contact details:
| Tel: | +44 20 7882 2425 |
| Fax: | +44 20 7882 2181 |
| Email: | o.marches@qmul.ac.uk |
| Address: | Centre for Immunology and Infectious Disease, |
Biography
I obtained my PhD in September 2003 from the University Paul Sabatier in Toulouse ( France ) working on molecular and cellular basis of pathogenic Escherichia coli virulence in the team of Dr Eric Oswald (Laboratoire Interactions Hotes-Agents Pathogenes (IHAP)). Then I was awarded a Marie Curie fellowship to conduct post-doctoral research in Pr Gad Frankel's lab at the Imperial College where I have carried on my studies on pathogenic E. coli from December 2003 to September 2007. Since October 2007, I have joined the Centre for Immunology and Infectious Disease within the Blizard Institute of Cell and Molecular Science, where I have been appointed as a Non-Clinical Lecturer in Bacteriology.
Research Activity
Enteropathogenic (EPEC) and enterohaemorrhagic (EHEC) Escherichia coli are important causes of acute gastroenteritis in humans.EPEC is a frequent cause of infantile diarrhoea in the developing world while EHEC causes a wide spectrum of illnesses ranging from mild diarrhoea to severe diseases, such as haemorrhagic colitis and haemolytic uraemic syndrome (HUS). My main research interest is to decipher the molecular cross-talk established between the EPEC or EHEC bacteria and their host with a long term aim being to identify new tracks to follow for development of therapeutics or control strategies for infections . A key element in EPEC and EHEC pathogenic strategy is their use of a type III secretion system to inject virulence proteins called effectors directly into host eukaryotic cells, proteins which subvert normal cellular functions. I am particularly interested in the identification and characterisation of these effectors and in the characterization of the host cellular processes they are targeting.
Key Publications
• Vossenkämper A, Marchès O, Fairclough PD, Warnes G, Stagg AJ, Lindsay JO, Evans PC, Luong le A, Croft NM, Naik S, Frankel G, MacDonald TT. Inhibition of NF-kappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol 2010, 185, 4118-4127.
• Vossenkämper A, MacDonald TT and Marchès O Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system. J Inflamm (Lond) 2011 May 3;8(1):11
• Pearson, J.S., Riedmaier, P., Marchès, O., Frankel, G. & Hartland, E.L. A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. Mol Microbiol 2011, 80, 219-230.
• Arbeloa, A., Oates, C.V., Marchès, O., Hartland, E.L. & Frankel, G. Enteropathogenic and enterohemorrhagic Escherichia coli type III secretion effector EspV induces radical morphological changes in eukaryotic cells. Infect Immun 2011, 2079, 1067-1076.
• Hemrajani C, Berger CN, Robinson SK, Marchès O, Mousnier A, Frankel G. NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection. Proc. Natl. Acad. Sci. USA 2010 Feb 16;107(7):3129-34.
• Munera D., Crepin VF, Marchès O, Frankel G. The N-terminal type III secretion signal of enteropathogenic E. coli translocators proteins. J. Bacteriol 2010 192, 3534-3539.
